van der Heijde D, Dougados M, Maksymowych WP, et al. - This study was intended to present the open-label extension (OLE) of the GO-AHEAD study assessing the long-term efficacy and safety of golimumab (GLM) in patients with non-radiographic axial spondyloarthritis (nr-axSpA). Researchers administered GLM 50 mg every 4 weeks during the OLE (36-week treatment; additional 8-week safety follow-up; GLM/GLM and placebo [PBO]/GLM groups) to the patients (both GLM- and placebo-treated in the double-blind phase). In this analysis, 189/198 (95.5%) entered the OLE; 174/198 patients (87.9%) completed all visits out of 198 patients. They found sustained improvement in clinical efficacy at 52 weeks in patients with nr-axSpA following GLM treatment. The findings revealed that GLM was well tolerated and provided substantial long-term benefits to patients with nr-axSpA.